Results 21 to 30 of about 4,744 (194)

The role of DPYD and the effects of DPYD suppressor luteolin combined with 5‐FU in pancreatic cancer

Cancer Medicine
Background Despite advances in the treatment of cancer, pancreatic ductal adenocarcinoma (PDAC) remains highly lethal due to the lack of effective therapies.
Hiroyuki Kato, Motonori Sato, Aya Naiki‐Ito, Shingo Inaguma, Makoto Sano, Masayuki Komura, Yuko Nagayasu, Kuang Xiaochen, Akihisa Kato, Yoichi Matsuo, Hideaki Ijichi, Satoru Takahashi   +11 more
doaj   +3 more sources

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy [PDF]

Journal of Experimental & Clinical Cancer Research, 2008
Background The activity of dihydropyrimidine dehydrogenase (DPD), the key enzyme of pyrimidine catabolism, is thought to be an important determinant for the occurrence of severe toxic reactions to 5-fluorouracil (5-FU), which is one of the most commonly
Aebi Stefan, Farese Simone, Amstutz Ursula, Largiadèr Carlo R   +3 more
doaj   +2 more sources

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients [PDF]

The Pharmacogenomics Journal, 2019
Dihydropyrimidine dehydrogenase (DPYD) is a highly polymorphic gene and classic deficient variants (i.e., c.1236G>A/HapB3, c.1679T>G, c.1905+1G>A and c.2846A>T) are characterized by impaired enzyme activity and risk of severe adverse drug reactions (ADRs) in patients treated with fluoropyrimidines. The identification of poor metabolizers by pre-emptive
Del Re, Marzia, Cinieri, Saverio, Michelucci, Angela, Salvadori, Stefano, Loupakis, Fotios, Schirripa, Marta, Cremolini, Chiara, Crucitta, Stefania, Barbara, Cecilia, Di Leo, Angelo, Latiano, Tiziana Pia, Pietrantonio, Filippo, Di Donato, Samantha, Simi, Paolo, Passardi, Alessandro, De Braud, Filippo, Altavilla, Giuseppe, Zamagni, Claudio, Bordonaro, Roberto, Butera, Alfredo, Maiello, Evaristo, Pinto, Carmine, Falcone, Alfredo, Mazzotti, Valentina, Morganti, Riccardo, Danesi, Romano   +25 more
openaire   +5 more sources

DPYD and UGT1A1 Genotype-Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant-Specific Impact on Treatment Intensity and Toxicity. [PDF]

Int J Cancer
Pre‐treatment DPYD and UGT1A1 genotyping is increasingly used to prevent fluoropyrimidine‐ and irinotecan‐related toxicity, but variant‐specific real‐world effects remain unclear. In an unselected cohort of cancer patients with actionable genotypes, genotype‐driven dosing improved safety while preserving treatment exposure in high‐risk DPYD c.1905+1G>A
Gambron M, Peruzzi E, Perfler S, Montico M, Cecchin R, De Mattia E, Spina M, Lisanti C, Corsetti S, Foltran L, Puglisi F, Roncato R, Cecchin E.   +12 more
europepmc   +2 more sources

Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study [PDF]

, 2023
Genetic variants; Cancer; SpainVariants genètiques; Càncer; EspanyaVariantes genéticas; Cáncer; EspañaIntroduction Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) gene is gaining importance to be able to predict fluoropyrimidine ...
Riera, Pau, Miarons, Marta, Gutiérrez Nicolás, Fernando, Manzaneque, Alba   +3 more
core   +4 more sources

Benchmark of Open-Access Star-Allele Callers to Accurately Assess Haplotypes and Phenotypes in Pharmacogenetic Studies. [PDF]

Clin Pharmacol Ther
Genetic polymorphisms are common in pharmacogenes, with sometimes important implications for drug metabolism. Assessing the correct enzyme phenotype from genetic data is thus a crucial step into the development of personalized medicine. Many bioinformatics star‐allele callers have been developed for this purpose of identifying the correct star alleles ...
Gros-La-Faige MB, Génin E, Herzig AF.
europepmc   +2 more sources

The Impact of Upfront DihydroPyrimidine Dehydrogenase (DPD) Testing on the Therapeutic Management of Patients Scheduled for 5-FU. [PDF]

Cancer Med
ABSTRACT Purpose 5‐fluorouracil (5‐FU) is catabolized by dihydropyrimidine dehydrogenase (DPD). DPD deficiency can trigger life‐threatening toxicities, and pretesting DPD is increasingly recommended. Here, we investigated the impact of upfront DPD testing on treatment strategy, that is, whether DPD status influences physicians' choice to use 5‐FU or ...
Kallee G, Salas S, Milano G, Duffaud F, Dahan L, Ciccolini J.   +5 more
europepmc   +2 more sources

Challenges in DPYD Test Implementation in Patients Treated with Fluoropyrimidines are DPYD Genotype Arriving on Time? [Letter]

Pharmacogenomics and Personalized Medicine, 2023
Marta López López-Cepero, Antonia Obrador de Hevia, Mónica Guillot Morales Hospital Universitario Son Espases, Palma de Mallorca, SpainCorrespondence: Marta López López-Cepero, Hospital Universitario Son Espases, Carretera de Valldemossa no.
López López-Cepero,Marta, Obrador de Hevia,Antonia, Guillot Morales,Mónica   +2 more
openaire   +4 more sources

DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol [PDF]

Farmacia Hospitalaria, 2021
Objective: The main purpose of this study is to evaluate the potential clinical impact of pharmacogenetic testing on the reduction of the toxicity in patients treated with fluoropyrimidines. This will be achieved by comparing the frequency of adverse
Ana Hernández-Guío, M.ª Ángeles Bernabéu-Martínez, Andrés Corno-Caparrós, M.ª Teresa Aznar-Saliente, Manuel Bonete-Sánchez, Miguel Ángel Calleja-Hernández   +5 more
doaj   +1 more source

Omics Biomarkers in Precision Oncology: From the Lens of the ASCPT Biomarkers and Translational Tools and Oncology Communities. [PDF]

Clin Transl Sci
ABSTRACT Omics biomarkers comprise several molecular entities, including genomic, epigenomic, transcriptomic, proteomic, and metabolomic signatures. They play an essential role in oncology drug development and clinical settings by enabling personalized medicine.
Mehanna M, Mody H, Hsu JC, Quintanilha J, Taylor ZL, James A, Rajbanshi B, Manchandani P, Chekka LM.   +8 more
europepmc   +2 more sources